Cargando…

Effect of food on capsule and granule formulations of selumetinib

Selumetinib is an oral, potent, and highly selective allosteric MEK1/2 inhibitor approved for the treatment of pediatric patients (aged ≥2 years) with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. A granule formulation of selumetinib is under development to impro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen‐Rabbie, Sarit, Mattinson, Alexandra, So, Karen, Wang, Nan, Goldwater, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010250/ https://www.ncbi.nlm.nih.gov/pubmed/35170228 http://dx.doi.org/10.1111/cts.13209

Ejemplares similares

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Huang, Hui-Ju, et al.
Publicado: (2021)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

Identification of the Major Degradation Pathways of Selumetinib
por: Bouchema, Tahar Sif eddine, et al.
Publicado: (2022)

Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
por: Blegen, Kristina, et al.
Publicado: (2022)

Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014)

Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
por: Patel, YT, et al.
Publicado: (2017)

Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018)

CORRIGENDUM: Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
Publicado: (2017)

Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies
por: Goldwater, Ronald, et al.
Publicado: (2017)

Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment
por: Zheng, Xiaohang, et al.
Publicado: (2022)

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
por: Chen, Yu-Luan, et al.
Publicado: (2023)

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
por: Dymond, Angela W., et al.
Publicado: (2017)

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
por: Johnson, Mark, et al.
Publicado: (2022)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer
por: Larson, Steven M., et al.
Publicado: (2017)

Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study
por: Suenobu, Souichi, et al.
Publicado: (2023)

Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
por: Tian, Zhuowei, et al.
Publicado: (2023)

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
por: LoRusso, Patricia M., et al.
Publicado: (2017)

Selumetinib produces a central core of apoptosis in breast cancer bone metastases in mice
por: Bosma, Nicholas A., et al.
Publicado: (2014)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
por: Prado, C M M, et al.
Publicado: (2012)

The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma
por: Lyons Rimmer, Jade, et al.
Publicado: (2020)

Isotretinoin Oil-Based Capsule Formulation Optimization
por: Tsai, Pi-Ju, et al.
Publicado: (2013)

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
por: Greystoke, Alastair, et al.
Publicado: (2017)

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Oral Selumetinib Does Not Negatively Impact Photoreceptor Survival in Murine Experimental Retinal Detachment
por: Cebulla, Colleen M., et al.
Publicado: (2019)

Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status
por: Zhang, Jun, et al.
Publicado: (2017)

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway
por: Li, Chen, et al.
Publicado: (2016)

Formulation and in vitro Evaluation of Floating Capsules of Theophylline
por: Bhise, S. B., et al.
Publicado: (2008)

Evaluation of the pharmacokinetics and food effects of a novel formulation tamsulosin 0.4 mg capsule compared with a 0.2 mg capsule in healthy male volunteers
por: Ban, Mu Seong, et al.
Publicado: (2020)

Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs
por: Wächter, Sabine, et al.
Publicado: (2018)

Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma
por: Blackwood, Nigel, et al.
Publicado: (2023)

Flow of Formulation Granules through a Conical Hopper
por: Mazumder, B., et al.
Publicado: (2008)

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects
por: Dymond, Angela W., et al.
Publicado: (2016)

The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo
por: Zou, Yun, et al.
Publicado: (2017)

Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells
por: Zhou, Yan, et al.
Publicado: (2016)

Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
por: Tamura, Satoshi, et al.
Publicado: (2020)

Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change
por: Baldo, Francesco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_261jer00ouh801lauh8dbdlov0